Literature DB >> 29369793

Alpha galactosidase A activity in Parkinson's disease.

R N Alcalay1, P Wolf2, O A Levy3, U J Kang4, C Waters4, S Fahn4, B Ford4, S H Kuo4, N Vanegas4, H Shah4, C Liong4, S Narayan4, M W Pauciulo5, W C Nichols5, Z Gan-Or6, G A Rouleau6, W K Chung7, P Oliva2, J Keutzer2, K Marder8, X K Zhang2.   

Abstract

Glucocerebrosidase (GCase, deficient in Gaucher disease) enzymatic activity measured in dried blood spots of Parkinson's Disease (PD) cases is within healthy range but reduced compared to controls. It is not known whether activities of additional lysosomal enzymes are reduced in dried blood spots in PD. To test whether reduction in lysosomal enzymatic activity in PD is specific to GCase, we measured GCase, acid sphingomyelinase (deficient in Niemann-Pick disease types A and B), alpha galactosidase A (deficient in Fabry), acid alpha-glucosidase (deficient in Pompe) and galactosylceramidase (deficient in Krabbe) enzymatic activities in dried blood spots of PD patients (n = 648) and controls (n = 317) recruited from Columbia University. Full sequencing of glucocerebrosidase (GBA) and the LRRK2 G2019S mutation was performed. Enzymatic activities were compared between PD cases and controls using t-test and regression models adjusted for age, gender, and GBA and LRRK2 G2019S mutation status. Alpha galactosidase A activity was lower in PD cases compared to controls both when only non-carriers were included (excluding all GBA and LRRK2 G2019S carriers and PD cases with age-at-onset below 40) [2.85 μmol/l/h versus 3.12 μmol/l/h, p = 0.018; after controlling for batch effect, p = 0.006 (468 PD cases and 296 controls)], and when including the entire cohort (2.89 μmol/l/h versus 3.10 μmol/l/h, p = 0.040; after controlling for batch effect, p = 0.011). Because the alpha galactosidase A gene is X-linked, we stratified the analyses by sex. Among women who were non-carriers of GBA and LRRK2 G2019S mutations (PD, n = 155; control, n = 194), alpha galactosidase A activity was lower in PD compared to controls (2.77 μmol/l/h versus 3.10 μmol/l/h, p = 0.044; after controlling for a batch effect, p = 0.001). The enzymatic activity of acid sphingomyelinase, acid alpha-glucosidase and galactosylceramidase was not significantly different between PD and controls. In non-carriers, most lysosomal enzyme activities were correlated, with the strongest association in GCase, acid alpha-glucosidase, and alpha galactosidase A (Pearson correlation coefficient between 0.382 and 0.532). In a regression model with all five enzymes among non-carriers (adjusted for sex and age), higher alpha galactosidase A activity was associated with lower odds of PD status (OR = 0.54; 95% CI:0.31-0.95; p = 0.032). When LRRK2 G2019S PD carriers (n = 37) were compared to non-carriers with PD, carriers had higher GCase, acid sphingomyelinase and alpha galactosidase A activity. We conclude that alpha galactosidase A may have a potential independent role in PD, in addition to GCase.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Lysosomal storage disease; Movement disorders; Neurodegeneration; Parkinson's disease

Mesh:

Substances:

Year:  2018        PMID: 29369793      PMCID: PMC5811339          DOI: 10.1016/j.nbd.2018.01.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  44 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Parkinsonism and Anderson Fabry's disease: a case report.

Authors:  Susanne Buechner; Maria Teresa Rosaria De Cristofaro; Silvia Ramat; Walter Borsini
Journal:  Mov Disord       Date:  2006-01       Impact factor: 10.338

3.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

4.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

5.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Authors:  Johannes M Aerts; Johanna E Groener; Sijmen Kuiper; Wilma E Donker-Koopman; Anneke Strijland; Roelof Ottenhoff; Cindy van Roomen; Mina Mirzaian; Frits A Wijburg; Gabor E Linthorst; Anouk C Vedder; Saskia M Rombach; Josanne Cox-Brinkman; Pentti Somerharju; Rolf G Boot; Carla E Hollak; Roscoe O Brady; Ben J Poorthuis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.

Authors:  Z Gan-Or; N Giladi; U Rozovski; C Shifrin; S Rosner; T Gurevich; A Bar-Shira; A Orr-Urtreger
Journal:  Neurology       Date:  2008-04-23       Impact factor: 9.910

7.  [An autopsied case of Fabry's disease presenting with parkinsonism and cardiomegaly as a cardinal clinical manifestation].

Authors:  S Orimo; T Iwasaki; H Yoshino; M Arai; E Hiyamuta
Journal:  Rinsho Shinkeigaku       Date:  1994-10

8.  Acceleration of α-synuclein aggregation by exosomes.

Authors:  Marie Grey; Christopher J Dunning; Ricardo Gaspar; Carl Grey; Patrik Brundin; Emma Sparr; Sara Linse
Journal:  J Biol Chem       Date:  2014-11-25       Impact factor: 5.157

9.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci.

Authors:  Diana Chang; Mike A Nalls; Ingileif B Hallgrímsdóttir; Julie Hunkapiller; Marcel van der Brug; Fang Cai; Geoffrey A Kerchner; Gai Ayalon; Baris Bingol; Morgan Sheng; David Hinds; Timothy W Behrens; Andrew B Singleton; Tushar R Bhangale; Robert R Graham
Journal:  Nat Genet       Date:  2017-09-11       Impact factor: 38.330

10.  Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice.

Authors:  Michael P Nelson; Tonia E Tse; Darrel B O'Quinn; Stefanie M Percival; Edgar A Jaimes; David G Warnock; John J Shacka
Journal:  Acta Neuropathol Commun       Date:  2014-02-14       Impact factor: 7.801

View more
  23 in total

Review 1.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

2.  Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation.

Authors:  Harsh Shah; Christopher Liong; Oren A Levy; Cheryl Waters; Stanley Fahn; Karen Marder; Un J Kang; Pavlina Wolf; Petra Oliva; Kate Zhang; Roy N Alcalay; Jose Gutierrez
Journal:  Stroke       Date:  2018-08       Impact factor: 7.914

3.  Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.

Authors:  Daniel Ysselstein; Joshua M Shulman; Dimitri Krainc
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 4.  GBA1 and The Immune System: A Potential Role in Parkinson's Disease?

Authors:  Zaid A M Al-Azzawi; Saman Arfaie; Ziv Gan-Or
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.

Authors:  Nurit Omer; Nir Giladi; Tanya Gurevich; Anat Bar-Shira; Mali Gana-Weisz; Tal Glinka; Orly Goldstein; Meir Kestenbaum; Jesse M Cedarbaum; Omar S Mabrouk; Kyle B Fraser; Julia C Shirvan; Avi Orr-Urtreger; Anat Mirelman; Avner Thaler
Journal:  Mov Disord       Date:  2021-09-22       Impact factor: 9.698

6.  Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson's disease.

Authors:  Bouchra Ouled Amar Bencheikh; Konstantin Senkevich; Uladzislau Rudakou; Eric Yu; Kheireddin Mufti; Jennifer A Ruskey; Farnaz Asayesh; Sandra B Laurent; Dan Spiegelman; Stanley Fahn; Cheryl Waters; Oury Monchi; Yves Dauvilliers; Alberto J Espay; Nicolas Dupré; Lior Greenbaum; Sharon Hassin-Baer; Guy A Rouleau; Roy N Alcalay; Edward A Fon; Ziv Gan-Or
Journal:  Neurobiol Aging       Date:  2020-04-08       Impact factor: 4.673

7.  Lipidomics Prediction of Parkinson's Disease Severity: A Machine-Learning Analysis.

Authors:  Hila Avisar; Cristina Guardia-Laguarta; Estela Area-Gomez; Matthew Surface; Amanda K Chan; Roy N Alcalay; Boaz Lerner
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 8.  Highlights on Genomics Applications for Lysosomal Storage Diseases.

Authors:  Valentina La Cognata; Maria Guarnaccia; Agata Polizzi; Martino Ruggieri; Sebastiano Cavallaro
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

9.  Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.

Authors:  Luciana Paim-Marques; Amanda Virginia Cavalcante; Islane Verçosa; Paula Carneiro; Marcia Souto-Maior; Erlane Marques; Simone Appenzeller
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

Review 10.  Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease.

Authors:  Sophia R L Vieira; Huw R Morris
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.